

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for Trelagliptin succinate tablet from the National Medical Products Administration of China to conduct its bioequivalence trials and clinical trials for Type 2 diabetes.

Trelagliptin succinate tablet is a long-acting selective dipeptidyl peptidase 4 (“DPP-4”) inhibitor which can selectively and persistently inhibit DPP-4 when taken only once a week. Trelagliptin succinate tablet can be used as a single drug or in combination with other oral hypoglycemic drugs. It has unique advantages of not resulting hypoglycemia, not causing weight gain, and having few side effects especially low incidence of gastrointestinal adverse events.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 23 November 2023

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.